SCHEMBL4316358

SCHEMBL4316358

Cc1ccsc1C(=O)Nc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.56
AURKB Q96GD4 2/20 0.56
KIT P10721 2/20 0.40
FLT3 P36888 1/20 0.40
BACE1 P56817 3/20 0.39
GBA1 P04062 1/20 0.38
P2RX7 Q99572 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CCNK O75909 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCND3 P30281 1/20 0.37
CDK9 P50750 1/20 0.37
CDK6 Q00534 1/20 0.37
TSHR P16473 1/20 0.37
NAMPT P43490 2/20 0.37
LMNA P02545 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4316361 1.00 AURKA (0.56) AURKAAURKBKITFLT3BACE1
SCHEMBL4322572 0.90 AURKA (0.56) AURKAAURKBKITFLT3BACE1
SCHEMBL4320733 0.90 AURKA (0.60) AURKAAURKBKITFLT3SMN1; SMN2
SCHEMBL4320741 0.90 AURKA (0.60) AURKAAURKBKITFLT3SMN1; SMN2
SCHEMBL5265469 0.90 AURKA (0.60) AURKAAURKBKITFLT3SMN1; SMN2
SCHEMBL4314913 0.89 AURKA (0.58) AURKAAURKBKITFLT3SMN1; SMN2
SCHEMBL4314905 0.89 AURKA (0.58) AURKAAURKBKITFLT3SMN1; SMN2
SCHEMBL31814 0.89 AURKA (0.71) AURKAAURKB
SCHEMBL4326955 0.87 AURKA (0.58) AURKAAURKBKITFLT3SMN1; SMN2
SCHEMBL4326949 0.87 AURKA (0.58) AURKAAURKBKITFLT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885KIT 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.